A Simple Blood Test Detects Suicidal Tendencies in Individuals with Major Depressive Disorder
By LabMedica International staff writers Posted on 06 May 2022 |
A gene expression signature found in blood and brain tissue from individuals with major depressive disorder seemed to be associated with the likelihood of development of suicidal behavior.
Suicide is a serious global public health problem that accounts for close to 800,000 deaths per year, and since major depressive disorder (MDD) is the most common diagnosis among suicides, identifying those at the highest risk for suicide is a pressing challenge.
To meet this challenge, investigators at the University of California, Irvine (USA) collected blood and dorsolateral prefrontal cortex (DLPFC) samples from MDD patients who died by suicide (MDD-S), MDDs who died by other means (MDD-NS), and non-psychiatric controls. Gene expression was analyzed using RNA and the NanoString (Seattle, WA, USA) platform.
Results revealed 14 genes in the blood samples that significantly differentiated MDD-S versus MDD-NS. The top six genes differentially expressed in blood were: PER3, MTPAP, SLC25A26, CD19, SOX9, and GAR1. Additionally, four genes showed significant changes in brain and blood between MDD-S and MDD-NS; SOX9 was decreased and PER3 was increased in MDD-S in both tissues, while CD19 and TERF1 were increased in blood but decreased in DLPFC. These changes in gene expression reflected stress response, including polyamine metabolism, circadian rhythm, immune dysregulation, and telomere maintenance.
“These blood biomarkers are an important step toward developing blood tests to identify patients with imminent risk of ending their lives,” said senior author Dr. Adolfo Sequeira, associate researcher in the department of psychiatry and human behavior at the University of California, Irvine. “To our knowledge, this is the first study to analyze blood and brain samples in a well-defined population of MDDs demonstrating significant differences in gene expression associated with completed suicide.”
The study was published in the April 14, 2022, online edition of the journal Translational Psychiatry.
Related Links:
University of California, Irvine
NanoString
Latest Molecular Diagnostics News
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety